These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 33240417)

  • 1. Plasma plastin-3: A tumor marker in patients with non-small-cell lung cancer treated with nivolumab.
    Kuriyama K; Yokobori T; Sohda M; Nakazawa N; Yajima T; Naruse I; Kuwano H; Shirabe K; Kaira K; Saeki H
    Oncol Lett; 2021 Jan; 21(1):11. PubMed ID: 33240417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant expression of plastin-3 via copy number gain induces the epithelial-mesenchymal transition in circulating colorectal cancer cells.
    Sugimachi K; Yokobori T; Iinuma H; Ueda M; Ueo H; Shinden Y; Eguchi H; Sudo T; Suzuki A; Maehara Y; Mori M; Mimori K
    Ann Surg Oncol; 2014 Oct; 21(11):3680-90. PubMed ID: 24217791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A common gene variant in PLS3 predicts colon cancer recurrence in women.
    Szkandera J; Winder T; Stotz M; Weissmueller M; Langsenlehner T; Pichler M; Samonigg H; Renner W; Gerger A; Absenger G
    Tumour Biol; 2013 Aug; 34(4):2183-8. PubMed ID: 23549633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plastin 3 down-regulation augments the sensitivity of MDA-MB-231 cells to paclitaxel via the p38 MAPK signalling pathway.
    Ma Y; Lai W; Zhao M; Yue C; Shi F; Li R; Hu Z
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):685-695. PubMed ID: 30829071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non-Small-cell Lung Cancer.
    Okuma Y; Wakui H; Utsumi H; Sagawa Y; Hosomi Y; Kuwano K; Homma S
    Clin Lung Cancer; 2018 Sep; 19(5):410-417.e1. PubMed ID: 29859759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab.
    Nakaya A; Kurata T; Yoshioka H; Takeyasu Y; Niki M; Kibata K; Satsutani N; Ogata M; Miyara T; Nomura S
    Int J Clin Oncol; 2018 Aug; 23(4):634-640. PubMed ID: 29442281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plastin-3 is a diagnostic and prognostic marker for pancreatic adenocarcinoma and distinguishes from diffuse large B-cell lymphoma.
    Xiong F; Wu GH; Wang B; Chen YJ
    Cancer Cell Int; 2021 Aug; 21(1):411. PubMed ID: 34348730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Actin Binding Protein Plastin-3 Is Involved in the Pathogenesis of Acute Myeloid Leukemia.
    Velthaus A; Cornils K; Hennigs JK; Grüb S; Stamm H; Wicklein D; Bokemeyer C; Heuser M; Windhorst S; Fiedler W; Wellbrock J
    Cancers (Basel); 2019 Oct; 11(11):. PubMed ID: 31717802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating tumour cell-derived plastin3 is a novel marker for predicting long-term prognosis in patients with breast cancer.
    Ueo H; Sugimachi K; Gorges TM; Bartkowiak K; Yokobori T; Müller V; Shinden Y; Ueda M; Ueo H; Mori M; Kuwano H; Maehara Y; Ohno S; Pantel K; Mimori K
    Br J Cancer; 2015 Apr; 112(9):1519-26. PubMed ID: 25880010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer.
    Carbone F; Grossi F; Bonaventura A; Vecchié A; Minetti S; Bardi N; Elia E; Ansaldo AM; Ferrara D; Rijavec E; Dal Bello MG; Biello F; Rossi G; Tagliamento M; Alama A; Coco S; Spallarossa P; Dallegri F; Genova C; Montecucco F
    Clin Exp Metastasis; 2019 Oct; 36(5):449-456. PubMed ID: 31376097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
    Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
    J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of Vitamin D in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab.
    Cusato J; Genova C; Tomasello C; Carrega P; Ottonello S; Pietra G; Mingari MC; Cossu I; Rijavec E; Leggieri A; Di Perri G; Dal Bello MG; Coco S; Boccardo S; Ferlazzo G; Grossi F; D'Avolio A
    Cancers (Basel); 2019 Jan; 11(1):. PubMed ID: 30669662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.
    Bagley SJ; Kothari S; Aggarwal C; Bauml JM; Alley EW; Evans TL; Kosteva JA; Ciunci CA; Gabriel PE; Thompson JC; Stonehouse-Lee S; Sherry VE; Gilbert E; Eaby-Sandy B; Mutale F; DiLullo G; Cohen RB; Vachani A; Langer CJ
    Lung Cancer; 2017 Apr; 106():1-7. PubMed ID: 28285682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiotherapy is an independent prognostic marker of favorable prognosis in non-small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab.
    Yamaguchi O; Kaira K; Hashimoto K; Mouri A; Miura Y; Shiono A; Nishihara F; Murayama Y; Noda SE; Kato S; Kobayashi K; Kagamu H
    Thorac Cancer; 2019 Apr; 10(4):992-1000. PubMed ID: 30888716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy.
    Lee JS; Lee KH; Cho EK; Kim DW; Kim SW; Kim JH; Cho BC; Kang JH; Han JY; Min YJ; Park K
    Lung Cancer; 2018 Aug; 122():234-242. PubMed ID: 30032838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Novel Peptide Probe for Identification of PLS3-Expressed Cancer Cells.
    Shi F; Ma Y; Qian Y; Wang Y; Wang Z; Zhao M; Hu Z
    Anal Chem; 2019 Aug; 91(15):9640-9647. PubMed ID: 31293151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYFRA 21-1 predicts the efficacy of nivolumab in patients with advanced lung adenocarcinoma.
    Shirasu H; Ono A; Omae K; Nakashima K; Omori S; Wakuda K; Kenmotsu H; Naito T; Murakami H; Endo M; Nakajima T; Takahashi T
    Tumour Biol; 2018 Feb; 40(2):1010428318760420. PubMed ID: 29463190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low plasma miR-25 expression is a favorite prognosis factor in non-small cell lung cancer.
    Zhang YL; Zhang ZL; Zhu XB; Xu L; Lu P; Xu M; Liu WJ; Zhang XY; Yao HM; Ye XW
    Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5251-5259. PubMed ID: 31298376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer.
    Sekine K; Kanda S; Goto Y; Horinouchi H; Fujiwara Y; Yamamoto N; Motoi N; Ohe Y
    Lung Cancer; 2018 Oct; 124():179-188. PubMed ID: 30268458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plastin3 is associated with epithelial-mesenchymal transition and poor prognosis in gastric cancer.
    Kurashige J; Yokobori T; Mima K; Sawada G; Takahashi Y; Ueo H; Takano Y; Matsumura T; Uchi R; Eguchi H; Sudo T; Sugimachi K; Mori M; Baba H; Mimori K
    Oncol Lett; 2019 Feb; 17(2):2393-2399. PubMed ID: 30675305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.